Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Directly Reprogrammed Human Neurons Identify a Pathogenic Mechanism of Valproic Acid at Early Developmental Stages

ABSTRACT: Directly Reprogrammed Human Neurons Identify a Pathogenic Mechanism of Valproic Acid at Early Developmental Stages

PROVIDER: PRJNA530578 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8838550_1.fastq.gz	Fastqsanger.gz
	SRR8838550_2.fastq.gz	Fastqsanger.gz
	SRR8838541_1.fastq.gz	Fastqsanger.gz
	SRR8838541_2.fastq.gz	Fastqsanger.gz
	SRR8838551_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 44

Similar Datasets

Directly Reprogrammed Human Neurons Identify a Pathogenic Mechanism of Valproic Acid at Early Developmental Stages

Project description:Human pluripotent stem cells can be rapidly converted into functional neurons by ectopic expression of proneural transcription factors. Here we show that directly reprogrammed neurons, despite their rapid maturation kinetics, can model teratogenic mechanisms that specifically affect early neurodevelopment. We delineated distinct phases of in vitro maturation during reprogramming of human neurons and assessed the cellular phenotypes of valproic acid (VPA), a teratogenic drug. VPA exposure caused chronic impairment of dendritic morphology and functional properties of developing neurons, but not those of mature neurons. These pathogenic effects were associated with VPA-mediated inhibition of the histone deacetylase (HDAC) and glycogen synthase kinase-3 (GSK-3) pathways, which caused transcriptional downregulation of many genes, including MARCKSL1, an actin-stabilizing protein essential for dendritic morphogenesis and synapse maturation during early neurodevelopment. Our findings identify a developmentally restricted pathogenic mechanism of VPA and establish the use of reprogrammed neurons as an effective platform for modeling teratogenic pathways.

2019-05-28 | GSE129241 | GEO

Organoids derived from directly reprogrammed human hepatocytes for modeling liver cancer initiation

Project description:Organoids derived from directly reprogrammed human hepatocytes for modeling liver cancer initiation

| PRJNA476313 | ENA

Autophagy impairments in directly reprogrammed neurons in patients with idiopathic Parkinson’s disease

Project description:Autophagy impairments in directly reprogrammed neurons in patients with idiopathic Parkinson’s disease

| PRJNA515626 | ENA

Autophagy impairments in directly reprogrammed neurons in patients with idiopathic Parkinson’s disease

Project description:Protein degradation impairment is strongly suspected to play a role in idiopathic Parkinson’s disease (PD). However, current tools and models are lacking to study such disease associated phenotypes across the PD patient population. Here, we generate functional induced dopaminergic neurons (iDANs) directly reprogrammed from adult dermal fibroblasts of patients with PD to investigate intra-neuronal autophagy alterations.

2019-06-01 | GSE125239 | GEO

Metabolic characterization of directly reprogrammed renal tubular epithelial cells (iRECs)

Project description:Fibroblasts can be directly reprogrammed to induced renal tubular epithelial cells (iRECs) using four transcription factors. These engineered cells may be used for disease modeling, cell replacement therapy or drug and toxicity testing. Direct reprogramming induces drastic changes in the transcriptional landscape, protein expression, morphological and functional properties of cells. However, how the metabolome is changed by reprogramming and to what degree it resembles the target cell type remains unknown. Using untargeted gas chromatography-mass spectrometry (GC-MS) and targeted liquid chromatography-MS, we characterized the metabolome of mouse embryonic fibroblasts (MEFs), iRECs, mIMCD-3 cells, and whole kidneys. Metabolic fingerprinting can distinguish each cell type reliably, revealing iRECs are most similar to mIMCD-3 cells and clearly separate from MEFs used for reprogramming. Treatment with the cytotoxic drug cisplatin induced typical changes in the metabolic profile of iRECs commonly occurring in acute renal injury. Interestingly, metabolites in the medium of iRECs, but not of mIMCD-3 cells or fibroblast could distinguish treated and non-treated cells by cluster analysis. In conclusion, direct reprogramming of fibroblasts into renal tubular epithelial cells strongly influences the metabolome of engineered cells, suggesting that metabolic profiling may aid in establishing iRECs as in vitro models for nephrotoxicity testing in the future.

2021-08-20 | MTBLS608 | MetaboLights

Genome wide gene expression profiling and methylation profiling of directly reprogrammed osteoblasts from mouse fibroblasts

Project description:Genome wide gene expression profiling and methylation profiling of directly reprogrammed osteoblasts from mouse fibroblasts

| PRJNA587510 | ENA

Transcription profiling of human embryonic stem cells in response to valproic acid and valproic acid analogs

Project description:Transcriptional profiling of valproic acid and valproic acid analogs in human embryonic stem cells.

2010-12-31 | E-MEXP-2374 | biostudies-arrayexpress

Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons

Project description:Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons

| PRJNA828261 | ENA

CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a dystrophic mouse model

Project description:CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a dystrophic mouse model

| PRJNA691306 | ENA

Responder and non-responder proteomic and phosphoproteomic profiles to ATRA/Valproic acid before treatment

Project description:Proteomic and phosphoproteomic raw files from responder and non-responder acute myeloid leukemia patient samples before initiation of ATRA/valproic acid treatment

2021-09-10 | PXD024110 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data